Compare BANF & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BANF | AMLX |
|---|---|---|
| Founded | 1984 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.8B |
| IPO Year | 1994 | 2021 |
| Metric | BANF | AMLX |
|---|---|---|
| Price | $106.83 | $27.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $124.00 | $42.36 |
| AVG Volume (30 Days) | 107.2K | ★ 1.4M |
| Earning Date | 10-20-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.95% | N/A |
| EPS Growth | 10.40 | ★ 65.46 |
| EPS | ★ 3.81 | N/A |
| Revenue | N/A | ★ $380,786,000.00 |
| Revenue This Year | $8.64 | N/A |
| Revenue Next Year | $7.04 | N/A |
| P/E Ratio | $28.06 | ★ N/A |
| Revenue Growth | N/A | ★ 1612.94 |
| 52 Week Low | $101.48 | $10.83 |
| 52 Week High | $126.14 | $41.14 |
| Indicator | BANF | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 43.29 | 36.48 |
| Support Level | $106.28 | $12.97 |
| Resistance Level | $116.82 | $34.35 |
| Average True Range (ATR) | 2.06 | 1.36 |
| MACD | 0.01 | -0.61 |
| Stochastic Oscillator | 45.36 | 17.50 |
BancFirst Corp is engaged in providing banking services. The company's business unit includes BancFirst metropolitan banks, BancFirst community banks, Pegasus Bank, Worthington, other financial services and executive, operations and support. BancFirst metropolitan banks, BancFirst community banks, Pegasus and Worthington offer traditional banking products such as commercial and retail lending and a full line of deposit accounts. Its Other financial services are specialty product business units including guaranteed small business lending, residential mortgage lending, trust services, securities brokerage, electronic banking, and insurance.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.